ONXEO
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.
ONXEO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1997-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.onxeo.com
Total Employee:
11+
Status:
Active
Contact:
+330145587600
Total Funding:
60.4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Alix
Alix SA is a biotechnology company that develops drugs for the identification of therapeutic targets.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Prestizia
Prestizia is a biotechnology company that is developing a microRNA1 technology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-02-29 | DNA Therapeutics | DNA Therapeutics acquired by Onxeo | 1.85 M USD |
| 2007-06-27 | TopoTarget Switzerland | TopoTarget Switzerland acquired by Onxeo | N/A |
| 2002-06-04 | TopoTarget UK Limited | TopoTarget UK Limited acquired by Onxeo | N/A |
Investors List
Invus
Invus investment in Post-IPO Equity - Onxeo
Financière de la Montagne
Financière de la Montagne investment in Post-IPO Equity - Onxeo
Bpifrance
Bpifrance investment in Post-IPO Equity - Onxeo
Oséo
Oséo investment in Grant - Onxeo
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-07 | Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer |
| 2022-01-03 | Onxeo Appoints Julien Miara as New Interim CEO |
Official Site Inspections
http://www.onxeo.com Semrush global rank: 5.13 M Semrush visits lastest month: 1.59 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Onxeo"
Onxeo Company Profile - Office Locations, Competitors, Revenue …
Feb 12, 2021 Onxeo is a biotechnology company, that develops drugs for the treatment of orphan oncology diseases worldwide. The Company offers Beleodaq for the treatment of …See details»
ONXEO - VentureRadar
Onxeo’s most valuable asset is its employees who have built a unique expertise in developing and registering drugs. The Company has successfully led two products to registration, including …See details»
Onxeo - Funding, Financials, Valuation & Investors - Crunchbase
Feb 29, 2016 Onxeo is registered under the ticker EPA:ONXEO . Onxeo is funded by 5 investors. Invus and Financière de la Montagne are the most recent investors. Onxeo has …See details»
Onxeo - PharmaBoardroom
Dec 17, 2015 Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. ... Dr …See details»
Onxeo changes its name and becomes Valerio Therapeutics …
Paris (France), June 6, 2023 – 6:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the …See details»
Onxeo Reports its Half-Year 2022 Financial Results and Provides an ...
Sep 13, 2022 Dr. Shefali Agarwal, President and CEO of Onxeo, said: "This first half of the year has been an opportunity for Onxeo to undergo profound transformations, both in its …See details»
Onxeo - Contacts, Employees, Board Members, Advisors & Alumni …
Onxeo has 2 current employee profiles, including President & Chief Executive Officer Shefali Agarwal. Shefali Agarwal President & Chief Executive Officer. Valerie Leroy Director, Investor …See details»
Onxeo : Inside Information / News release on accounts, results
Sep 13, 2022 Dr. Shefali Agarwal, President and CEO of Onxeo, said: "This first half of the year has been an opportunity for Onxeo to undergo profound transformations, both in its …See details»
Onxeo Appoints Dr. Shefali Agarwal as President and Chief …
Apr 7, 2022 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»
Onxeo Reports Full Year 2022 Financial Results and Provides …
Apr 24, 2023 Onxeo (Euronext Growth Paris: ALONX) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique …See details»
Onxeo Appoints Dr. Shefali Agarwal as President and Chief …
Apr 7, 2022 She is also on the Scientific Advisory Board of Imvax, Inc. and is the Founder of Cancer Shakti Foundation, a voluntary non-profit organization dedicated to raising cancer …See details»
Onxeo Reports its Financial Results for the First Half of
September 17, 2020 12:29 ET | Source: Onxeo SA Onxeo SA The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, provides …See details»
Onxeo: Publication of the 2021 Annual Financial Report
Apr 28, 2022 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»
Onxeo Continues to Strengthen its Board of Directors
Nov 23, 2021 Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap [email protected] +33 1 44 71 94 98See details»
Onxeo — Next generation of DNA damage repair inhibitors
Sep 16, 2019 Onxeo reported a cash position of €6.3m at end-Q219. In June 2019, the company announced that it had renewed a 12-month equity financing line with Nice & Green. Remaining …See details»
Onxeo Reports its Full-Year 2021 Financial Results and Announces ...
Apr 6, 2022 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»
Onxeo Reports Full-Year 2020 Financial Results and Provides …
Apr 21, 2021 Judith Greciet, Chief Executive Officer of Onxeo, declared: “2020 was marked for all by an unprecedented health crisis. Yet it will have allowed Onxeo to demonstrate the …See details»
Onxeo Further strengthens its Board of Directors with two
Oct 14, 2021 Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap [email protected] +33 1 44 71 94 98See details»
Onxeo Further strengthens its Board of Directors with two …
Oct 14, 2021 Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding …See details»